



News Release

Suven Life Sciences secures 3rd Canadian and 6th Eurasian Patent for their NCE.

HYDERABAD, INDIA (May' 12 2010) – Suven Life Sciences Ltd (Suven) announces today that the **Canadian Patent Office has issued a 3rd product Patent # 2,507,923 and Eurasian Patent office has granted 6th product patent # 12750** corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid until 2023 and 2025 respectively.

The granted claims of the patents include the class of **selective 5-HT compounds discovered by Suven** and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's, ADHD, Parkinson, Schizophrenia and Huntington's diseases.

These issued patents are for the same inventions that of the granted patents in various other countries like USA Europe etc for their NCE. These **granted patents are exclusive intellectual property of Suven** and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various stages of clinical development like at Phase-I or Phase-II.

"We are very pleased by the grant of these 2 patents to Suven by Canadian Patent Office and Eurasian Patent office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated \$20 billion market potential globally" says Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. **The Company has twelve (12) internally discovered therapeutic drug candidates** currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to **developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.**

For more information on Suven/ACT, please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;